*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Brenda Mattox
Summary Sentence: Mark E. Davis, PhD - 26th Annual Ashton Clay Lecture, Keynote Address
Full Summary: Mark E. Davis, PhD - California Institute of Technology
Mark E. Davis, PhD - Warren and Katharine Schlinger Professor of Chemical Engineering at the California Institute of Technology and a member of the Experimental Therapeutics Program of the Colmprehensive Cancer Center at the City of HopeFor centuries, cancer has been one of the most devastating diseases. Papyrus writings from 1600-1500 BC describe cancer and attempts at its treatment. Today, the molecular basis of cancer is being unraveled, and new therapeutics are being developed to take advantage of this new knowledge. One class of experimental therapeutics involves the use of nanoparticles. Given the long history of difficulties in developing cancer therapies, why is there excitement about nanoparticle medicine (nanomedicines) for fighting cancer? Is it warranted or is it hype? In this lecture, I will present the current understandings of why nanoparticle medicines have the potential to provide “game changing” ways to treat cancer. I will illustrate the various features and potentials of nanoparticle medicines using two different nanoparticles that we have translated from laboratory curiosities to experimental therapeutics in human clinical trials.
